Mid-Term Performance of Clinical LINAC in Volumetric Modulated Arc Therapy

Abstract

Background: The mid-term performance of clinical linear accelerator (LINAC) during volumetric modulated arc therapy (VMAT) treatment period is not performed in clinical practice and usually replaced with one-time plan quality assurance (QA). In this research we aim to monitor daily reproducibility of VMAT delivery from tracking individual leaf movement error and dosimetric error to evaluate the mid-term quality of the machine used. Materials and Methods: First, multileaf collimator (MLC) information was imported into MATLAB program to determine which of the MLC leaves in the leaf bank had the maximum RMS position error (maxRMS). We estimated where the maximum positional errors (maxPE) of the chosen leaf occur along its path length and tracked its daily variations over the entire treatment period. Secondly, picture information of dosimetric error from portal dosimetry was imported into MATLAB where representative high gamma index region (HGR) was determined as HGR with length of > 1 cm and their centers were daily tracked. Results and Discussion: The maxPEs in the brain and tongue cases were distributed broader than in other cases, but all data were found located within ± 0.5 mm. From first day to last day all of five cases show the similar visual pattern of HGRs and Centers of the longest HGRs remained within ± 1 mm of that in first day. These findings prove excellent mid-term performance of the LINAC used in VMAT treatments over a full course of treatment. Conclusion: Tracking the daily location changes of leaf movement and dosimetric error can be a good indicator of predicting the daily quality like stability and reproducibility of beam delivering in VMAT treatment.

Dosimetric Comparison of Noncoplanar and Coplanar Volumetric Modulated Arc Therapy Plans for Esophageal Cancer

“…An estimated 1,600 new patients are diagnosed with esophageal cancer every year [1]. Treatment options for esophageal cancer are surgery, chemotherapy, or radiotherapy [2][3][4][5][6][7][8]. Radiotherapy for inoperable or unresectable esophageal cancer plays a crucial role in achieving optimal tumor control along with reducing normal tissue complications.…”